Daily Respiratory Research Analysis
Analyzed 83 papers and selected 3 impactful papers.
Summary
Analyzed 83 papers and selected 3 impactful articles.
Selected Articles
1. Tudor domain-containing protein 9-targeting siRNA nanoparticles alleviate Pseudomonas aeruginosa lung injury in preclinical models by promoting neutrophil cuproptosis.
Using a hyaluronic acid–coated peptide nanoparticle, the authors delivered siRNA against TDRD9 to neutrophils, which increased neutrophil cuproptosis and reduced inflammation and edema in Pseudomonas aeruginosa lung injury models. Mechanistic work identified a PD-L1/CD80/p38 MAPK axis by which TDRD9 suppresses cuproptosis; targeting TDRD9 improved outcomes in mice and reduced bacterial growth and inflammation in human lung organoids.
Impact: Introduces a first-in-class host-directed nanotherapy that reprograms neutrophil death pathways to treat bacterial lung injury, supported by multi-system validation. It opens a new therapeutic avenue beyond antibiotics for drug-resistant pneumonia.
Clinical Implications: If safety and delivery are confirmed in humans, TDRD9-siRNA nanoparticles could complement antibiotics to reduce neutrophil-driven tissue injury in severe P. aeruginosa pneumonia, including multidrug-resistant cases.
Key Findings
- HA-coated peptide nanoparticles efficiently delivered siRNA targeting TDRD9 to neutrophils identified from patient BALF RNA-seq.
- Silencing TDRD9 promoted neutrophil cuproptosis, reduced pulmonary neutrophil accumulation, and alleviated lung inflammation and edema in mouse models.
- Mechanistically, TDRD9 upregulated PD-L1 via CD80 interaction to activate p38 MAPK, thereby suppressing cuproptosis; inhibiting this axis improved outcomes.
- In human lung organoids, HA–siTDRD9 reduced bacterial growth, apoptosis, and inflammatory readouts.
Methodological Strengths
- Translational validation across patient-derived BAL neutrophils, murine adoptive transfer models, and human lung organoids.
- Mechanistic dissection of PD-L1/CD80/p38 MAPK signaling linking TDRD9 to neutrophil cuproptosis, with targeted nanodelivery.
Limitations
- Preclinical study without human safety or efficacy data; translational hurdles for pulmonary siRNA delivery remain.
- Biodistribution, off-target effects, and durability of response were not fully characterized.
Future Directions: Advance to large-animal safety/pharmacology and first-in-human studies; optimize dosing, aerosolized delivery, and combination with antibiotics in multidrug-resistant pneumonia.
Pseudomonas aeruginosa pneumonia poses a significant therapeutic challenge. Nanoparticles serve as an effective tool for nucleic acid delivery to efficiently alleviate pneumonia. This study develops a hyaluronic acid (HA)-coated peptide nanoparticle system for targeted delivery of small interfering RNA (siRNA) against Tudor domain-containing protein 9 (TDRD9), identified via RNA sequencing of bronchoalveolar lavage fluid-derived neutrophils from 21 recruited patients (11 males/10 females). Adoptive transfer of TDRD9-silenced polymorphonuclear neutrophils into neutrophil-depleted male mice attenuates lung inflammation and edema. Mechanistically, TDRD9 suppresses neutrophil cuproptosis by upregulating programmed death ligand 1 (PD-L1) through interaction with CD80 to activate p38 mitogen-activated protein kinase (MAPK) signaling. HA-si-TDRD9 nanoparticles enhance neutrophil cuproptosis, reduce pulmonary neutrophil accumulation, and ameliorate lung injury via PD-L1/CD80/MAPK. Importantly, HA-si-TDRD9 nanoparticles reduce bacterial growth, apoptosis, and inflammation in human lung organoids. This work demonstrates that targeting TDRD9 with siRNA nanoparticle platform presents a promising therapeutic strategy for treating bacterial lung injury.
2. HS-20093, a B7-H3-targeted antibody-drug conjugate in lung cancer: Results from the ARTEMIS-001 phase 1a/b trial.
In a multicenter phase 1a/b trial, the B7-H3 ADC HS-20093 showed a 52.3% confirmed ORR in ES-SCLC and 22.4% in NSCLC at 8–10 mg/kg, with hematologic toxicities and a 3.4% incidence of treatment-related ILD. An 8.0 mg/kg dose was selected for phase 3 based on efficacy and safety.
Impact: Demonstrates robust antitumor activity of a novel B7-H3 ADC across lung cancer histologies with a defined safety profile, informing dose selection and trial design for phase 3 studies.
Clinical Implications: Supports B7-H3 ADCs as promising options for previously treated ES-SCLC and NSCLC; clinicians should anticipate hematologic toxicity and monitor for interstitial lung disease when these agents enter practice.
Key Findings
- Maximum tolerated dose established at 12.0 mg/kg; 8.0 mg/kg selected for phase 3.
- Confirmed ORR was 52.3% in ES-SCLC (N=65) and 22.4% in NSCLC (N=152) at 8–10 mg/kg, with comparable activity across doses.
- Most frequent grade ≥3 treatment-related AEs were neutropenia, leukopenia, and anemia; treatment-related ILD occurred in 3.4% and fatal AEs in 3.8%.
Methodological Strengths
- Large phase 1a/b dataset with predefined dose-escalation and expansion across lung cancer cohorts.
- Comprehensive safety characterization including hematologic events and ILD, alongside efficacy signals.
Limitations
- Non-randomized early-phase design without a comparator; survival endpoints immature.
- Potential selection bias and limited follow-up to assess durability and rare toxicities.
Future Directions: Proceed to randomized phase 3 trials in ES-SCLC and NSCLC, refine ILD risk mitigation, and explore biomarkers (B7-H3 expression, hematologic profiles) for patient selection.
This phase 1a/b study (NCT05276609) evaluated the safety, pharmacokinetics, and efficacy of B7-H3-targeted antibody-drug conjugate HS-20093 (GSK5764227) in 306 patients with previously treated advanced solid tumors. In phase 1a, 12.0 mg/kg was established as the maximum tolerated dose. Among 236 lung cancer patients who received 8.0 or 10.0 mg/kg HS-20093, the most frequent grade ≥3 treatment-related adverse events (AEs) included decreased neutrophil (25.5% vs. 50.5%) and white blood cell counts (19.7% vs. 42.4%), and anemia (16.8% vs. 34.3%), respectively. Treatment-related interstitial lung disease and AEs leading to death occurred in 3.4% and 3.8% of patients, respectively. Among response-evaluable patients, the confirmed objective response rate was 52.3% (95% CI: 39.5, 64.9) for extensive-stage SCLC (ES-SCLC, N = 65) and 22.4% (95% CI: 16.0, 29.8) for non-small cell lung cancer (NSCLC, N = 152) patients, with comparable rates between 8.0 mg/kg and 10.0 mg/kg dose cohorts across both groups. These results support further development of HS-20093, with 8.0 mg/kg selected for phase 3 trials.
3. Cost-Effectiveness of Immunising Interventions to Reduce Respiratory Syncytial Virus Disease Burden in Infants in Australia.
An individual-based dynamic transmission and cost-effectiveness model suggests that a combined program—maternal RSV vaccination with a birth-dose monoclonal antibody for unprotected newborns—would likely be cost-saving, averting ~41% of infant hospitalizations and reducing QALY loss by 33% in Australia. Results are sensitive to disease burden ascertainment, costs, product efficacy/duration, and delivery timing/coverage.
Impact: Provides timely, policy-relevant evidence that a pragmatic combination of maternal vaccination and infant monoclonal antibodies could both lower RSV hospitalizations and save costs at a national level.
Clinical Implications: Health systems should consider implementing a combined maternal vaccine plus birth-dose mAb strategy for RSV, while monitoring real-world effectiveness, costs, and equitable coverage to optimize impact.
Key Findings
- A maternal RSV vaccine supplemented by a birth-dose monoclonal antibody for unprotected newborns is projected to be cost-saving versus status quo.
- The combined program averts on average 41% of infant hospitalizations annually and reduces QALY losses by 33%.
- Impact and cost-effectiveness are sensitive to assumptions on disease burden ascertainment, hospitalization and dose costs, product efficacy/duration, and delivery timing/coverage.
Methodological Strengths
- Individual-based dynamic transmission model linked to clinical pathways and cost-effectiveness, enabling comprehensive scenario and sensitivity analyses.
- Health system perspective with outcomes expressed in QALYs and hospitalizations averted, supporting policy translation.
Limitations
- Model-based estimates rely on assumptions about burden ascertainment, costs, and product performance; external validity may vary by setting.
- Does not replace the need for real-world effectiveness studies of maternal RSV vaccines and infant monoclonal antibody programs.
Future Directions: Integrate emerging real-world effectiveness, price, and coverage data to refine models; assess equity impacts and optimize delivery strategies under budget constraints.
BACKGROUND: Two immunising products are emerging to prevent the burden of respiratory syncytial virus (RSV) in infants: long-lasting monoclonal antibodies (mAbs) and maternal vaccines given during pregnancy (MV). This study assesses the potential cost-effectiveness of programs involving each product to help inform policy decisions related to their implementation in the Australian context. METHODS: We developed an individual-based dynamic transmission model of RSV infection, linked to a clinical pathways model and cost-effectiveness model. We modelled key scenarios exploring varying eligibility and coverage of immunisation products for at-risk and not-at-risk populations, in addition to sensitivity analyses of immunisation characteristics, program costs and the impact of potential under-ascertainment of RSV burden. We estimated the cost-effectiveness of each program from a health system perspective, with results presented as incremental cost-effectiveness ratios in terms of cost per quality-adjusted life year gained (QALY). RESULTS: We found a combined program in which administration of MV during pregnancy is supplemented with a birth-dose of mAbs for newborns born without protection from MV is likely to be cost-saving, compared with the status quo of no MV or mAbs delivered. This program averted on average 41% of infant hospitalisations per year and reduced QALY losses by 33%. CONCLUSIONS: Programs combining infant immunisation products are likely to significantly reduce the burden of RSV disease in Australia, and be cost-saving. However, their estimated impact and cost-effectiveness is strongly dependent on key assumptions (i) the consistency and completeness of ascertainment of disease burden over time; (ii) the cost of a hospitalisation and immunising dose; (iii) the efficacy and durability of protection of the modelled products; and (iv) the timing and coverage of the immunisation delivery. Respiratory syncytial virus in infants causes significant disease burden in Australia and worldwide. Multiple immunising products are emerging—vaccines given during pregnancy to protect the newborn, and long-lasting monoclonal antibodies given to infants—but it is uncertain what the impact of these products will be at a population level. We found, using an individual-based model, that a combined program of products is likely to be cost-saving from a health system perspective.